Danaher Corp

• Wall Street upgrades and UBS ratings changes drove Illumina stock upward. • Illumina will rejoin the S&P 500 index during rebalancing. • Annual revenue reached $4.34 billion with a net profit of $850 million.

• Danaher reaffirmed its third-quarter and full-year financial guidance. • Julie Sawyer Montgomery will assume the CEO role on October 1. • Danaher reports annual revenue of $24.57B and net profit of $3.61B.

• Danaher narrowed its full-year core revenue growth projections following second-quarter results. • Outgoing leadership announced a transition alongside subsequent disclosures of executive share sales. • The company reported latest annual revenue of $24.57B and net profit of $3.61B.

• Danaher reported second-quarter revenue and adjusted earnings exceeding Wall Street consensus estimates. • Julie Sawyer Montgomery was appointed as the new chief executive officer. • Danaher generated $24.57B in annual revenue with $3.61B in net profit.

• Thermo Fisher raised its full-year outlook following strong second-quarter financial results. • The company sold its microbiology business to Astorg for over one billion dollars. • Institutional managers and hedge funds recently built fresh positions in the company.

• Thermo Fisher exceeded quarterly earnings estimates and raised full-year organic revenue guidance. • Increased pharmaceutical capital expenditure and demand for clinical services boosted the company's backlog. • Technical indicators suggest a buy signal with an average analyst price target of $634.52.